CD19 and non-Hodgkin lymphoma: Prophylactic tocilizumab (1 hour prior to infusion of anti-CD19 CAR-T cells in patients with non-Hodgkin’s lymphoma) has been also associated with a low incidence and severity of CRS, with no detected adverse effects and no increase in the frequency or severity of neural pathology.